Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Personalized Dendritic Cell Injection ZSNeo-DC1.1 in the Treatment of Recurrent or Progressive High-grade Glioma

NCT06253234 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT06253234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06253234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Personalized Dendritic Cell Injection ZSNeo-DC1.1 in the Treatment of Recurrent or Progressive High-grade Glioma
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 2, 2024
Completion date
December 31, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

who grade iii gliomas, who grade iv gliomas